本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603882 证券简称：金域医学 公告编号：2024-040 广州金域医学检验集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 | 回购方案首次披露日 | 2024/4/16 | | | --- | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | | 预计回购金额 | 5,000 万元 | 万元~5,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 705,000 | 股 | | 累计已回购股数占总股本比例 | 0.1504% | | | 累计已回购金额 | 2,903.79 | 万元 | | 实际回购价格区间 | 38.05 元/股 | 元/股~46.97 | 2024 年 4 月 16 日，公司实施首次回购，截至 2024 年 4 月 30 日，本次回购方 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-039 公司股东圣域钫为梁耀铭先生控制的合伙企业，直接持有公司无限售流通 股股份 21,000,000 股，占公司总股本的 4.48%。本次补充质押股份 1,000,000 股，占圣域钫直接持有公司股份数的 4.76%，占公司总股本的 0.21%。 本次股份补充质押后，公司控股股东、实际控制人梁耀铭先生及其一致行 动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 23,840,000 股，占其持有公司股份总数的 14.45%，占公司总股 本的 5.09%。 一、上市公司股份补充质押 广州金域医学检验集团股份有限公司（以下简称"公司"）控股股东、实际 控制人梁耀铭先生于 2023 年 4 月 4 日、2023 年 11 月 7 日及 2024 年 2 月 27 日 办理了部分股份质押手续（公告编号：2023-007、2023-057 及 2024-018）。近日 公司接到梁耀铭先生的通知，获悉梁耀铭先生于 2024 年 4 月 29 日办理了股份补 充质押手续。 公司股东广州市圣域钫投资咨询合伙企业（有限合伙）（以 ...

Investment Rating - The report maintains a "Recommended" rating for the company Jin Yu Medical (金域医学) [1][2]. Core Views - The company has experienced significant revenue and profit declines due to changes in industry conditions and impairment provisions, but the long-term outlook remains positive [1][2]. - The company achieved a revenue of 8.54 billion yuan in 2023, a decrease of 44.82%, with a net profit of 643 million yuan, down 76.64% [1]. - The first quarter of 2024 saw a revenue of 1.84 billion yuan, a decline of 13.05%, and a net loss of 19 million yuan [1]. Financial Performance Summary - In 2023, the company reported a significant drop in revenue and profits, primarily due to reduced demand for testing services related to public health events [1]. - The company’s regular medical testing business generated revenue of 7.73 billion yuan in 2023, with a year-on-year growth of 15.35% [1]. - The company completed the development of 412 new projects in 2023, contributing 638 million yuan in revenue [1]. Future Outlook - The revenue target for 2024 has been adjusted to 9.3 billion yuan, with projected net profits of 981 million yuan, reflecting a growth of 52.52% year-on-year [2][3]. - The company is focusing on digital transformation to improve operational efficiency and profitability, leveraging big data and automation technologies [1]. - The report anticipates that the industry will see a consolidation phase post-competition, benefiting leading companies like Jin Yu Medical [1].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's revenue for 2023 was 8.54 billion yuan, a year-on-year decrease of 44.82%, with a net profit attributable to shareholders of 0.6438 billion yuan, down 76.64% year-on-year [4][6] - The decline in performance is attributed to a significant reduction in COVID-19 testing demand, increased credit impairment losses, and a slowdown in the growth of routine medical testing business [4][6] - Despite the overall decline, the routine medical testing business showed a robust growth of 15.35% year-on-year, with revenues reaching 7.73 billion yuan [4][6] - The company has developed 412 new projects in 2023, contributing 0.638 billion yuan in revenue, with notable growth in specific diagnostic areas [4][6] Financial Summary - The company's main revenue for 2022 was 15.48 billion yuan, with a net profit of 2.75 billion yuan [3][7] - For 2024, the expected revenue is 9.20 billion yuan, with a projected net profit of 0.663 billion yuan [3][7] - The earnings per share (EPS) for 2024 is estimated at 1.41 yuan, with a price-to-earnings (P/E) ratio of 26.94 [3][7] - The company’s overall gross margin decreased by 6.65 percentage points to 36.48% in 2023, influenced by industry competition and policy changes [4][6] Future Outlook - The company is expected to recover and achieve net profits of 1.06 billion yuan and 1.43 billion yuan in 2025 and 2026, respectively [6][7] - The report suggests a reasonable target price of 45.40 to 56.75 yuan per share for 2025, based on a P/E ratio of 20-25 times [6][7]

Investment Rating - The report maintains a "Recommended" investment rating for the company [1][2]. Core Views - The company's overall revenue for 2023 was 8.54 billion yuan, a decrease of 44.82% year-on-year, primarily due to reduced testing demand related to public health events. However, routine medical testing revenue showed a recovery with a 15.35% year-on-year increase, reaching 7.73 billion yuan [2][3]. - The company is accelerating its digital transformation, achieving significant results with its "Medical Testing 4.0" initiative, which includes the establishment of specialized disease databases and the implementation of automated and intelligent systems to enhance laboratory efficiency [2][3]. - Despite a short-term performance pressure in Q1 2024, with revenue of 1.84 billion yuan (down 13.05% year-on-year) and a net loss of 19 million yuan, the long-term growth momentum remains intact. The company plans to enhance its core capabilities through cost management, new product development, and digital transformation [2][3]. Financial Summary - For 2023, the company reported total revenue of 8.54 billion yuan, with a year-on-year growth rate of -44.8%. The net profit attributable to shareholders was 643 million yuan, down 76.6% year-on-year [3]. - The forecast for net profit attributable to shareholders for 2024, 2025, and 2026 is adjusted to 1.11 billion yuan, 1.34 billion yuan, and 1.61 billion yuan, respectively, with corresponding P/E ratios of 16, 13, and 11 times [2][3]. - The company's total market value is approximately 17.86 billion yuan, with a current share price of 38.10 yuan [6].

Summary of Conference Call Company/Industry Involved - The document pertains to a conference call related to a company's annual report and its first quarter 2024 report. Core Points and Arguments - The conference call was initiated to discuss the annual report and the first quarter 2024 results, indicating a focus on financial performance and strategic outlook for the upcoming period [1]. Other Important but Possibly Overlooked Content - The call emphasized the importance of institutional investor engagement, suggesting that the company values feedback and interaction with its investors [1].

Investment Rating - The investment rating for the company is not explicitly stated in the provided report, but it can be inferred that the company is viewed positively based on the growth projections and strategic initiatives discussed. Core Insights - The company reported a significant decline in revenue and net profit for 2023, with total revenue of 8.54 billion yuan, down 44.82% year-over-year, and a net profit of 0.643 billion yuan, down 76.64% year-over-year. However, the conventional medical diagnostic services segment showed a recovery with a revenue increase of 15.35% year-over-year, reaching 7.726 billion yuan in 2023 [1][2]. - The company is focusing on high-quality development in conventional medical diagnostic services, with a notable increase in revenue from core disease lines, including a 30.32% growth in neurological and psychiatric disease diagnostics and a 49.74% growth in infectious disease diagnostics [1][2]. - The company is accelerating its digital transformation to enhance profitability, implementing AI technologies to improve operational efficiency and customer experience. The gross profit margin for 2023 was reported at 36.48% [1][2]. Financial Performance Summary - In 2023, the company achieved total revenue of 8.54 billion yuan, with a year-over-year growth rate of -44.8%. The projected revenues for 2024, 2025, and 2026 are 9.713 billion yuan, 11.364 billion yuan, and 13.307 billion yuan, respectively, with expected growth rates of 13.7%, 17.0%, and 17.1% [2][3]. - The net profit attributable to the parent company for 2023 was 0.643 billion yuan, a decrease of 76.6% year-over-year. The forecasted net profits for the next three years are 0.676 billion yuan, 0.966 billion yuan, and 1.329 billion yuan, with growth rates of 5.1%, 42.9%, and 37.5% [2][3]. - The company's gross margin for 2023 was 36.5%, down from 43.1% in 2022, with expectations for gradual recovery in profitability as cost reduction measures take effect [1][2].

广州金域医学检验集团股份有限公司 2023 年度独立董事述职报告 本人作为广州金域医学检验集团股份有限公司（以下简称"公司"）第三届 董事会独立董事，严格按照《公司法》、《上市公司独立董事管理办法》、《公 司章程》、《独立董事工作制度》等规定，在 2023 年度工作中，忠实履行独立 董事的职责，积极参加股东大会、董事会、各专门委员会等会议，认真审议各项 议案并对相关事项发表意见，切实维护公司和全体股东特别是中小股东的合法权 益。现就 2023 年度履职情况汇报如下： 一、独立董事基本情况 余玉苗, 男，出生于 1965 年，中国国籍，无境外永久居留权。博士研究生 学历。1986 年毕业于武汉大学，获得经济学学士；1997 年毕业于武汉大学，获 得经济学博士。1989 年至 1996 年，任武汉大学经济学院会计与审计系讲师；1996 年至 2001 年，任武汉大学经济学院会计与审计系副教授、系副主任；2001 年至 2013 年，任武汉大学经济与管理学院会计系教授、博士生导师、系副主任；曾 任美国加州大学厄湾分校和香港科技大学访问学者；2013 年至今，任武汉大学 经济与管理学院会计系教授、博士生导师。2017 ...

金域医学管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业务办理》的相关规定编制了后附的 2023 年度非经营性资金 占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、合法和完整是金域医学管理层 的责任。我们将汇总表所载信息与我们审计金域医学公司 2023 年度 财务报表时所审核的会计资料及已审计财务报表中披露的相关内容 进行了核对，没有发现在重大方面存在不一致的情况。 专项报告第1页 广州金域医学检验集团股份有限公司 关联方占用资金专项审计说明 2023 年度 关于广州金域医学检验集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZA11790 号 广州金域医学检验集团股份有限公司全体股东： 我们审计了广州金域医学检验集团股份有限公司(以下简称"金 域医学")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母 公司资产负债表、2023 年度合并及母公司利润表、 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 证券代码：603882 证券简称：金域医学 公告编号：2024-037 广州金域医学检验集团股份有限公司 关于计提资产减值准备的公告 | | 按信用风险特征组合计提坏账准备的计提方法 | | | --- | --- | --- | | 组别 | 内容 | 计提方法 | | 组合一 | 合并范围内关联方应收款项及保证金 | 不计提 | | 组合二 | 除对单项金额重大并已单项计提或单项金额虽 | 账龄分析法 | | | 不重大但已单项计提坏账准备的应收账款和组 | | | | 合一之外的应收款项，公司根据以前年度与之 | | | | 相同或类似的、按账龄段划分的具有类似信用 | | | | 风险特征的应收款项组合 | | 为了客观、公允地反映广州金域医学检验集团股份有限公司（以下简称"公 司"）的财务状况以及经营成果，根据《企业会计准则》相关规定和公司会计政 策，公司对合并报表范围内各项资产进行了减值测试，相应计提资产减值准备。 详见下表： 单位：人民 ...